ArticleCureus2025
Evaluating Elevated CRP Levels as an Infection Marker: Implications for Chemotherapy Cycles in Lung Cancer Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimInfection is a prevalent cause of mortality and morbidity in patients with lung cancer. Moreover, infection diagnosis is challenging in such patients. C-reactive protein (CRP) is a frequently used marker in the clinical diagnosis of infection. Notwithstanding the foregoing, CRP may already be elevated in cases of malignant neoplasms, and in addition to malignancy, causal factors such as noninfectious infarction, inflammation, injury, drug reactions, and thrombosis may also be frequently associated with elevated CRP in such patients. The present study investigated the situations wherein higher CRP levels could be considered as the manifestation of infection that might hinder chemotherapy procedures and aimed to determine a cutoff value that could predict infection.
methodThis study prospectively included patients with lung cancer and high CRP values. The clinical features of the patients, along with laboratory and radiographic results, were assessed. Considering the final decision of the physician who followed up with the patients, they were divided into two groups: infected and noninfected groups. Intergroup comparisons were performed for clinical, laboratory, and radiological results. The receiver operating characteristic curve analysis was used to review the diagnostic value of serum CRP levels in predicting infection in patients with lung cancer. The CRP cutoff value to be considered for predicting infection was calculated.
resultsAt the time of admission, the mean CRP level of the 180 patients included in the study was 4.5 mg/dL. As per the physician's decision, 23 patients (12.8%) were found to have an infection. For the 23 infected patients, the mean CRP value at admission was 13.0 mg/dL, whereas it was 3.36 mg/dL for the 157 patients who were considered to be noninfected. The mean CRP value of the infected patients was significantly higher compared to that of the noninfected patients (
conclusionThis study suggested cutoff values to distinguish infection-associated high CRP levels from other causal factors that might induce an increase in CRP levels in patients admitted for chemotherapy administration. The suggested cutoff values can prevent unnecessary delays in chemotherapy cycles by eliminating false considerations of infection in patients with high CRP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.